The No-Phone Walk: The Simplest Thing You Can Do for Your Mental Health
There is a particular kind of walk many of us take every day. We answer a text before...
The U.S. Food and Drug Administration has approved Lipfendra, or enlicitide, the first oral medication designed to inhibit PCSK9 and lower LDL cholesterol.
Lipfendra is a once-daily tablet approved for adults with high cholesterol, including those with heterozygous familial hypercholesterolemia, an inherited condition that can cause very high LDL cholesterol. The medication is approved as an addition to diet and exercise—not as a replacement for them.¹
For patients who need more help lowering LDL, particularly those who have established cardiovascular disease, inherited cholesterol disorders, or persistently elevated cholesterol despite other treatments, the approval represents an important new option.
But experts within the Plant Strong medical community say the medication should be understood as one layer in a broader prevention strategy.
“Lifestyle is not the preliminary step we rush through before prescribing medication. It is the foundation upon which every other treatment should be built.”— DR. BRIAN ASBILL
What is PCSK9?
LDL receptors on the surface of liver cells help remove LDL cholesterol from the bloodstream.
PCSK9 is a protein that contributes to the breakdown of those receptors. When PCSK9 is blocked, more LDL receptors remain available to clear LDL cholesterol from the blood.
Other PCSK9 inhibitors have been available as injections. Lipfendra is the first FDA-approved medication to inhibit PCSK9 in a tablet taken by mouth.¹
The convenience of a daily pill could make this class of treatment more practical for some patients, especially those who prefer not to use injectable medication.
Lipfendra produced substantial reductions in LDL cholesterol
The FDA based its approval on two randomized, double-blind, placebo-controlled trials involving 3,207 adults who were already receiving maximally tolerated statin therapy.
Among participants with established atherosclerotic cardiovascular disease or an elevated risk of developing it, Lipfendra reduced LDL cholesterol by an average of approximately 56% compared with placebo after 24 weeks.
Among participants with heterozygous familial hypercholesterolemia, the average reduction was approximately 59%.¹
Those are significant changes in an important cardiovascular risk factor.
“This degree of LDL reduction is substantial. For patients who remain above a safe LDL level after meaningful lifestyle change and appropriate first-line therapy, an oral PCSK9 inhibitor could become a valuable additional tool.” — DR. BRIAN ASBILL
Lower LDL is not yet the same as fewer heart attacks
The clinical trials supporting Lipfendra’s approval were designed primarily to determine how effectively the medication lowered LDL cholesterol.
They were not designed to establish whether Lipfendra reduces heart attacks, strokes, cardiovascular deaths, or other major cardiovascular events.
A separate cardiovascular-outcomes trial is underway to study whether enlicitide reduces major adverse cardiovascular events, including heart attack, ischemic stroke, coronary heart disease death, urgent revascularization, and certain serious complications of peripheral artery disease.²
That distinction is important.
LDL cholesterol is a well-established causal contributor to atherosclerotic cardiovascular disease, and lowering LDL is a central goal of prevention and treatment. But evidence that a medication lowers a risk marker is not identical to direct evidence that the medication prevents clinical events.
“Lipfendra has demonstrated that it can substantially lower LDL cholesterol. We do not yet have direct evidence that this particular medication prevents heart attacks, strokes, or cardiovascular deaths. Until those outcomes are reported, we should be precise about what the research has established.” — DR. BRIAN ASBILL
Lifestyle reaches beyond a single laboratory value
Medication can be highly effective at targeting a specific pathway. Lifestyle influences the wider biological environment in which cardiovascular disease develops.
A healthy dietary pattern, regular physical activity, tobacco avoidance, adequate sleep, healthy blood pressure, improved insulin sensitivity, and weight management can affect multiple cardiovascular risk factors at the same time.
The American Heart Association includes diet, physical activity, tobacco avoidance, sleep, body weight, blood cholesterol, blood glucose, and blood pressure among its essential measures of cardiovascular health. Higher overall cardiovascular-health scores are associated with a lower risk of cardiovascular disease and other major health outcomes.³
This is why lifestyle should not be viewed simply as something patients try before receiving “real” treatment. Lifestyle is treatment—and, when practiced consistently, may help prevent disease from developing or progressing in the first place.
“The goal should never be merely to improve a cholesterol number while leaving the conditions that allow cardiovascular disease to develop untouched. We must help patients create an internal environment that protects the artery wall every day, beginning with the food they eat.” — DR. CALDWELL B. ESSELSTYN JR.
Dr. Caldwell B. Esselstyn Jr. has spent decades studying the relationship between nutrition and coronary artery disease. His work has emphasized a whole-food, plant-based approach intended to reduce exposure to foods that contribute to vascular injury while supporting endothelial health—the health of the delicate inner lining of the arteries.
“Medication may lower LDL cholesterol, and for some patients it may be necessary. But medication should be added to—not substituted for—the daily nutritional choices that address the disease process at its foundation.” — DR. CALDWELL B. ESSELSTYN JR.
A stacked approach to cardiovascular prevention
Lifestyle and medication do not have to be framed as competitors.
“The most effective approach is often a stacked one: establish an intensive lifestyle foundation, measure the response, assess the patient’s total risk, and then add medication when lifestyle alone does not achieve a sufficiently safe LDL level.” — DR. BRIAN ASBILL
Medication may be particularly important for people with familial hypercholesterolemia, established cardiovascular disease, very high baseline LDL cholesterol, or other risk factors that make lifestyle change alone unlikely to achieve the necessary reduction.
Those patients should not be made to feel that taking medication represents a failure of lifestyle. At the same time, prescribing medication should not end the conversation about food, movement, sleep, tobacco, blood pressure, and metabolic health.
“A pill may target LDL cholesterol, but lifestyle affects the entire cardiovascular environment. It can influence blood pressure, insulin sensitivity, body weight, vascular function, physical capacity, sleep, and metabolic health—all factors that help determine whether someone ultimately experiences a heart attack or stroke.” — DR. BRIAN ASBILL
A meaningful advance—with an important perspective
Lipfendra is an encouraging therapeutic development. It offers patients and clinicians another potentially powerful way to lower LDL cholesterol, with the convenience of an oral medication.
But LDL reduction is one part of cardiovascular prevention. The ultimate goal is not simply a better laboratory report. It is fewer heart attacks, fewer strokes, less disability, and longer, healthier lives.
Until direct cardiovascular-outcomes data for Lipfendra are available, its most appropriate position is as an additional tool within a comprehensive prevention plan.
“Our greatest opportunity is not simply to manage coronary disease after it has developed. It is to give people the knowledge and tools to avoid creating the disease in the first place.” — DR. CALDWELL B. ESSELSTYN JR.
Lifestyle remains the foundation. Medication can then be added thoughtfully when a patient’s genetics, disease history, response to lifestyle, and overall cardiovascular risk indicate that more protection is needed.
Kickstart your lifestyle today
If you want to kickstart your lifestyle to incorporate more plants on your plate, Plant Strong is here to help. Stock your pantry with ready-to-eat meals, then load up on fruits, vegetables, and whole grains throughout the day. We're here to make it easier to eat more plants!
About Dr. Brian Asbill
Dr. Brian Asbill is a cardiologist and longtime member of the Plant Strong medical community. He serves on the faculty at Plant Strong retreats, where he helps participants understand cholesterol, cardiovascular risk, disease prevention, and the role of lifestyle in heart health.
He is also a key member of the Plant Strong research team, contributing clinical expertise to the evaluation and publication of health outcomes associated with intensive lifestyle change. His work focuses on preventive cardiology, cardiovascular risk reduction, and helping patients combine evidence-based lifestyle strategies with appropriate medical treatment.
About Dr. Caldwell B. Esselstyn Jr.
Dr. Caldwell B. Esselstyn Jr. is a physician, surgeon, researcher, and internationally recognized leader in the use of nutrition to prevent and address coronary artery disease. He spent more than three decades at Cleveland Clinic, where his roles included surgeon, clinician, researcher, president of the medical staff, and member of the Board of Governors.
His long-running research and clinical work have examined the use of whole-food, plant-based nutrition in patients with advanced coronary artery disease. He is the author of Prevent and Reverse Heart Disease and the founder of the Esselstyn Heart Disease Program, which teaches patients about cardiovascular disease and the role of nutrition in its prevention and potential reversal.⁴
This article is for educational purposes and is not a substitute for individualized medical advice. Patients should discuss cholesterol levels, cardiovascular risk, lifestyle changes, and medication decisions with their healthcare provider.
References
-
U.S. Food and Drug Administration. “FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults With High Cholesterol.” July 2026.
-
ClinicalTrials.gov. “A Study of Enlicitide Decanoate in Participants at High Cardiovascular Risk,” NCT06008756. The ongoing trial is evaluating major adverse cardiovascular events.
-
American Heart Association. “Life’s Essential 8” and “Diet and Lifestyle Recommendations.” These resources identify diet, activity, sleep, tobacco exposure, weight, cholesterol, blood glucose, and blood pressure as central components of cardiovascular health.
-
Cleveland Clinic. “Caldwell Esselstyn Jr., MD” and “The Esselstyn Heart Disease Program.”
-
Navar AM, et al. “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.” The New England Journal of Medicine. 2026.
-
Ballantyne CM, et al. “Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia.” JAMA.
